| Jun 14 |
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
|
| Jun 14 |
Avidity Biosciences raises $400M via stock offering
|
| Jun 14 |
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
|
| Jun 13 |
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
|
| Jun 12 |
Avidity Biosciences announces proposed offering of common stock
|
| Jun 12 |
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
|
| Jun 12 |
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
|
| Jun 12 |
Avidity gains on early Phase 1/2 data for muscle disorder therapy
|
| Jun 12 |
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
|
| Jun 12 |
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
|
